使用彩票来解决在为罕见疾病药物分配资源时的不确定性
Kenneth Bond1, Lars Sandman2, Erik Gustavsson3
1Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden bond.ken@gmail.com.
Journal of medical ethics
|May 12, 2025
概括
当为罕见疾病药物提供资金不确定时,彩票提供了一个公平的解决方案. 这项研究表明,随机选择可能更好,而不是先到先得,为分配这些重要的医疗保健资源提供服务.
科学领域:
- 卫生经济学 卫生经济学
- 生物伦理学生物伦理学
- 公共卫生政策 公共卫生政策
背景情况:
- 由于高成本和有限的资金,为罕见病药物 (DRDs) 分配医疗保健资源存在重大挑战.
- 对于DRDs的融资决策的不确定性是决策者面临的一个常见问题.
研究的目的:
- 评估使用彩票作为一种方法来解决DRD的资金不确定性.
- 为了比较彩票与"先到先得"的方法,关于正式的平等和道德价值观.
主要方法:
- 对抽奖的分析与DRD资金的"先来先服务"的分析.
- 审查彩票的实际实施问题,包括参与者识别和处理未被选中的案例.
- 评估基于彩票的资源分配中的伦理考虑.
主要成果:
- 彩票可以满足DRD资金的形式平等和某些实质/程序价值.
- 彩票的实际实施引发了关于参与者和"失败者"的具体伦理考虑.
- 随机选择过程,就像彩票一样,在道德上是合理的分配DRD资金.
结论:
- 在面对资金不确定性时,彩票提供了一种道德上合理的方法,用于分配用于罕见疾病药物的资金.
- 在特定的DRD资源分配场景中,随机选择可能是"先到先得"方法的更好选择.
- 彩票实施中的伦理考虑要求对参与者选择和未获得资助的参与者的结果给予谨慎的关注.
相关概念视频
Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


